Literature DB >> 24205836

Telemedicine barriers associated with regional quality measures.

Frederick North1, Sarah J Crane, Paul Y Takahashi, William J Ward, Sidna M Tulledge-Scheitel, Karen Ytterberg, Eric G Tangalos, Robert J Stroebel.   

Abstract

Telemedicine practitioners are familiar with multiple barriers to delivering care at a distance. Licensing and reimbursement barriers are well known and are being addressed at national and state levels by the American Telemedicine Association. Another telemedicine barrier comes in the form of quality measures for diabetes. Minnesota medical practices are currently being compared on the proportion of their patients with diabetes who have attained goals for blood pressure, low-density lipoprotein cholesterol, and hemoglobin A1C. The quality measure for blood pressure specifically excludes measurements taken by the patient, thus precluding blood pressure telemonitoring as a way to meet the blood pressure goal. To counter this barrier, advocacy in telemedicine is needed so that telemonitoring as a data collection tool is included in quality measures.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24205836     DOI: 10.1089/tmj.2013.0167

Source DB:  PubMed          Journal:  Telemed J E Health        ISSN: 1530-5627            Impact factor:   3.536


  3 in total

1.  Provision of telemedicine services by community health centers.

Authors:  Peter Shin; Jessica Sharac; Feygele Jacobs
Journal:  Online J Public Health Inform       Date:  2014-10-16

2.  Establishing Telemedicine in an Academic Total Joint Arthroplasty Practice: Needs and Opportunities Highlighted by the COVID-19 Pandemic.

Authors:  Sandesh S Rao; Alexander E Loeb; Raj M Amin; Gregory J Golladay; Adam S Levin; Savyasachi C Thakkar
Journal:  Arthroplast Today       Date:  2020-04-23

Review 3.  What is the evidence base for diagnosing hypertension and for subsequent blood pressure treatment targets in the prevention of cardiovascular disease?

Authors:  Claire L Schwartz; Richard J McManus
Journal:  BMC Med       Date:  2015-10-12       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.